

**A CYCLOPROPANO ANALOG OF 2',3'-DIDEOXYCYTIDINE:  
STEREOSELECTIVE FORMATION OF A [3,1,0] BICYCLIC  
SYSTEM *via* HOMOLOGOUS FERRIER REACTION**


Masami Okabe\* and Ruen-Chu Sun

Chemistry Research Department, Hoffmann-La Roche Inc.  
Nutley, New Jersey 07110


Summary: A synthesis of 2',3'- $\alpha$ -methylene-2',3'-dideoxycytidine is described in which the [3,1,0] bicyclic system and the glycosidic linkage were constructed simultaneously.

Reverse transcriptase inhibitors have thus far proven to be the most effective therapeutic agents for the treatment of acquired immune deficiency syndrome (AIDS)<sup>1</sup>. The most promising agents of this class of drugs are 2',3'-dideoxynucleosides, such as 3'-deoxy-3' $\alpha$ -azidothymidine (AZT) and 2',3'-dideoxycytidine (ddC),<sup>2</sup> which are capable of undergoing 5'-phosphorylation by host kinases but teleologically incapable of DNA chain continuation.


As part of our program concerned with finding new types of dideoxynucleosides with anti-HIV activity,<sup>3</sup> we sought to develop a new strategy for three-membered ring construction which could allow us to prepare a novel type of nucleosides, 2',3'- $\alpha$ -methylene-2',3'-dideoxynucleosides **1**. In order to construct the bicyclic system, we could start either from a five-membered ring or from a three-membered ring. However, neither approach assures selective formation of the desired  $\alpha$ -stereoisomer. Therefore, we chose to start with the six-membered perimeter of this [3,1,0] bicyclic ring system.



**1**




Our synthesis plan centered on compound **2** with its enol ether and a leaving group at C-4. The enol ether could displace the leaving group in a  $\text{S}_{\text{N}}2$  like manner to form the bicyclic cation **3** with the desired stereochemistry, and which could be trapped by a nucleophile. If the nucleophile is a pyrimidine or purine base, we could obtain the desired nucleoside in one step. The implementation of this plan starts with tri-*O*-acetyl-*D*-glucal **4**, from which the key precursor **10** is prepared in 60% overall yield. The first step (**4**  $\rightarrow$  **5**) is a Ferrier reaction<sup>4</sup> in which an acetoxy group is replaced by an ethoxy group in a  $\text{S}_{\text{N}}2'$  like manner.





References and Notes:

1. R. Dagani, *C&E News*, 1987, November 23, p. 41.
2. T. R. Webb, H. Mitsuya, S. Broder, *J. Med. Chem.*, 1988, *31*, 1475 and references cited therein.
3. M. Okabe, R.-C. Sun, S. Y.-K. Tam, L. J. Todaro, D. L. Coffen, *J. Org. Chem.*, 1988, *53*, 4780.
4. R. J. Ferrier, N. Prasad, *J. Chem. Soc. (C)*, 1969, 570.
5. After the treatment of **6** in AcOH-Ac<sub>2</sub>O, the ethoxy group of **6** was replaced by an acetoxy group along with the formation of **7**. The acetoxy group was eliminated during distillation; bath temp. 105-140° at 5 mm Hg. Use of a strong acid, such as p-TsOH, leads to decomposition of **7**.
6. Alternatively, compound **7** can be prepared by LiAlH<sub>4</sub> reduction of **5** (refluxing dioxane) followed by acetylation. B. Fraser-Reid, B. Radatus, *J. Am. Chem. Soc.*, 1970, *92*, 6661.
7. The stereochemistry of products were assigned on the basis of their <sup>1</sup>H NMR spectra; **12**: J<sub>1',2'</sub>=3.1 Hz, J<sub>3',4'</sub>=0 Hz. **13**: J<sub>1',2'</sub>=0 Hz, J<sub>3',4'</sub>=0 Hz.
8. **14**: mp 230°C (dec); [α]<sub>D</sub> -36.0° (C=0.49, MeOH); UV (water) 270 nm (ε 8,640); NMR (DMSO-d<sub>6</sub>) δ 0.32 (dt, J=4.6 and 4.3 Hz, 1H), 0.91 (dt, J=4.6 and 8.2 Hz, 1H), 1.88 (m, 2H), 3.40 (m, 2H), 3.92 (t, J=5.8 Hz, 1H), 4.96 (t, J=5.4 Hz, 1H), 5.70 (d, J=7.4 Hz, 1H), 5.84 (s, 1H), 7.08 (bs, 1H), 7.15 (bs, 1H), 7.84 (d, J=7.4 Hz, 1H). Anal. Calcd for C<sub>10</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>: C 53.81; H, 5.87; N, 18.82. Found: C, 53.74; H, 5.81; N, 18.84.
9. A related reaction has been described, in which a [4,1,0] bicyclic system was constructed from a six-membered ring. S. Y.-K. Tam, B. Fraser-Reid, *Can. J. Chem.*, 1977, *55*, 3996.



(Received in USA 21 November 1988)